Estrogen receptor/progesterone receptor (ER/PR) positive breast cancers tend to grow more slowly than ER/PR negative cancers, and are more likely to respond to hormone therapy.
来源期刊 The Breast 研究点推荐 Luminal B/HER2-negative-like subtype 0关于我们 百度学术集成海量学术资源,融合人工智能、深度学习、大数据分析等技术,为科研工作者提供全面快捷的学术服务。在这里我们保持学习的态度,不忘初心,砥砺前行。了解更多>> 友情链接 ...
Luminal B/HER2-negative-like subtype is a predictor for local recurrence after breast-conserving surgery and shows no interaction with randomizationdoi:10.1016/s0960-9776(17)30340-5Wickberg, ?.Magnuson, A.Holmberg, L.Liljegren, G.The Breast...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
% Annexin V-positive/7-AAD positive cells in E is the sum of the percentages of Annexin V-positive/7AAD-negative, Annexin V-positive/7AAD-positive and Annexin V-negative/7AAD-positive cells. *p-value < 0.05. F Indicated cell lines were cultured detached form the ECM in the absence (...
“The HER2-positive story gets better and better. The IO [immuno-oncology] story gets better and better across different diseases,” he said in an interview with OncologyLive®.“There was clear evidence of progress in each of the fronts but we’re still waiting on that big sea change. ...
Is it worth it to keep thrashing your legs and waving your arms and calling for help, or would it be better to fall under the water so everyone on the shore can waste no more time and get back to doing something more productive. A bit long-winded, but I suspect you get the point....
Only half of HER2E tumors are HER2A. A careful examination of the tran- scriptional HER2E subtype revealed that these tumors are enriched for ER-negative, yet AR-driven tumors. There is a therapeutic opportunity to treat AR-driven tu- mors with anti-androgen agents, or combine such agents...
Biomarker analyses showed the tumor to be HER2 negative, p-MMR, MSS, TMB 0, with a CPS score of 0. She received several lines of systemic therapy (TS-1, XELOX, ramucirumab/paclitaxel, and PRL3zumab) prior to joining the PIANO trial. After 1 cycle of PIPAC OXA and 4 cycles of ...
Parsley is a good dietary source of apigenin, which has been shown to exhibit potent growth-inhibitory effects in HER2+ breast cancer cells. Apigenin has also been shown to inhibit the growth of patient-derived triple negative (ER-/PR-/HER2-) organoids and sensitize triple negative cells to ...